Myeloid suppressor cell depletion augments antitumor activity in lung cancer.

Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer.Individual antibody mediated depleti...

Full description

Bibliographic Details
Main Authors: Minu K Srivastava, Li Zhu, Marni Harris-White, Upendra K Kar, Min Huang, Ming F Johnson, Jay M Lee, David Elashoff, Robert Strieter, Steven Dubinett, Sherven Sharma
Format: Article
Language:English
Published: Public Library of Science (PLoS) 2012-01-01
Series:PLoS ONE
Online Access:http://europepmc.org/articles/PMC3398024?pdf=render
_version_ 1818616795579285504
author Minu K Srivastava
Li Zhu
Marni Harris-White
Upendra K Kar
Min Huang
Ming F Johnson
Jay M Lee
David Elashoff
Robert Strieter
Steven Dubinett
Sherven Sharma
author_facet Minu K Srivastava
Li Zhu
Marni Harris-White
Upendra K Kar
Min Huang
Ming F Johnson
Jay M Lee
David Elashoff
Robert Strieter
Steven Dubinett
Sherven Sharma
author_sort Minu K Srivastava
collection DOAJ
description Myeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer.Individual antibody mediated depletion of MDSC (anti-Gr1 or anti-Ly6G) enhanced the antitumor activity against lung cancer. In comparison to controls, MDSC depletion enhanced the APC activity and increased the frequency and activity of the NK and T cell effectors in the tumor. Compared to controls, the anti-Gr1 or anti-Ly6G treatment led to increased: (i) CD8 T cells, (ii) NK cells, (iii) CD8 T or NK intracytoplasmic expression of IFNγ, perforin and granzyme (iv) CD3 T cells expressing the activation marker CD107a and CXCR3, (v) reduced CD8 T cell IL-10 production in the tumors (vi) reduced tumor angiogenic (VEGF, CXCL2, CXCL5, and Angiopoietin1&2) but enhanced anti-angiogenic (CXCL9 and CXCL10) expression and (vii) reduced tumor staining of endothelial marker Meca 32. Immunocytochemistry of tumor sections showed reduced Gr1 expressing cells with increased CD3 T cell infiltrates in the anti-Gr1 or anti-Ly6G groups. MDSC depletion led to a marked inhibition in tumor growth, enhanced tumor cell apoptosis and reduced migration of the tumors from the primary site to the lung compared to controls. Therapeutic vaccination responses were enhanced in vivo following MDSC depletion with 50% of treated mice completely eradicating established tumors. Treated mice that rejected their primary tumors acquired immunological memory against a secondary tumor challenge. The remaining 50% of mice in this group had 20 fold reductions in tumor burden compared to controls.Our data demonstrate that targeting MDSC can improve antitumor immune responses suggesting a broad applicability of combined immune based approaches against cancer. This multifaceted approach may prove useful against tumors where MDSC play a role in tumor immune evasion.
first_indexed 2024-12-16T16:55:29Z
format Article
id doaj.art-a0ab1d2f0c8840d2b257ab3a69022ed5
institution Directory Open Access Journal
issn 1932-6203
language English
last_indexed 2024-12-16T16:55:29Z
publishDate 2012-01-01
publisher Public Library of Science (PLoS)
record_format Article
series PLoS ONE
spelling doaj.art-a0ab1d2f0c8840d2b257ab3a69022ed52022-12-21T22:23:53ZengPublic Library of Science (PLoS)PLoS ONE1932-62032012-01-0177e4067710.1371/journal.pone.0040677Myeloid suppressor cell depletion augments antitumor activity in lung cancer.Minu K SrivastavaLi ZhuMarni Harris-WhiteUpendra K KarMin HuangMing F JohnsonJay M LeeDavid ElashoffRobert StrieterSteven DubinettSherven SharmaMyeloid derived suppressor cells (MDSC) are important regulators of immune responses. We evaluated the mechanistic role of MDSC depletion on antigen presenting cell (APC), NK, T cell activities and therapeutic vaccination responses in murine models of lung cancer.Individual antibody mediated depletion of MDSC (anti-Gr1 or anti-Ly6G) enhanced the antitumor activity against lung cancer. In comparison to controls, MDSC depletion enhanced the APC activity and increased the frequency and activity of the NK and T cell effectors in the tumor. Compared to controls, the anti-Gr1 or anti-Ly6G treatment led to increased: (i) CD8 T cells, (ii) NK cells, (iii) CD8 T or NK intracytoplasmic expression of IFNγ, perforin and granzyme (iv) CD3 T cells expressing the activation marker CD107a and CXCR3, (v) reduced CD8 T cell IL-10 production in the tumors (vi) reduced tumor angiogenic (VEGF, CXCL2, CXCL5, and Angiopoietin1&2) but enhanced anti-angiogenic (CXCL9 and CXCL10) expression and (vii) reduced tumor staining of endothelial marker Meca 32. Immunocytochemistry of tumor sections showed reduced Gr1 expressing cells with increased CD3 T cell infiltrates in the anti-Gr1 or anti-Ly6G groups. MDSC depletion led to a marked inhibition in tumor growth, enhanced tumor cell apoptosis and reduced migration of the tumors from the primary site to the lung compared to controls. Therapeutic vaccination responses were enhanced in vivo following MDSC depletion with 50% of treated mice completely eradicating established tumors. Treated mice that rejected their primary tumors acquired immunological memory against a secondary tumor challenge. The remaining 50% of mice in this group had 20 fold reductions in tumor burden compared to controls.Our data demonstrate that targeting MDSC can improve antitumor immune responses suggesting a broad applicability of combined immune based approaches against cancer. This multifaceted approach may prove useful against tumors where MDSC play a role in tumor immune evasion.http://europepmc.org/articles/PMC3398024?pdf=render
spellingShingle Minu K Srivastava
Li Zhu
Marni Harris-White
Upendra K Kar
Min Huang
Ming F Johnson
Jay M Lee
David Elashoff
Robert Strieter
Steven Dubinett
Sherven Sharma
Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
PLoS ONE
title Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
title_full Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
title_fullStr Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
title_full_unstemmed Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
title_short Myeloid suppressor cell depletion augments antitumor activity in lung cancer.
title_sort myeloid suppressor cell depletion augments antitumor activity in lung cancer
url http://europepmc.org/articles/PMC3398024?pdf=render
work_keys_str_mv AT minuksrivastava myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT lizhu myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT marniharriswhite myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT upendrakkar myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT minhuang myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT mingfjohnson myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT jaymlee myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT davidelashoff myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT robertstrieter myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT stevendubinett myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer
AT shervensharma myeloidsuppressorcelldepletionaugmentsantitumoractivityinlungcancer